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Abstract 
 
Mendelian randomization investigations are becoming more powerful and simpler to perform, due 
to the increasing size and coverage of genome-wide association studies and the increasing 
availability of summarized data on genetic associations with risk factors and disease outcomes. 
However, when using multiple genetic variants from different gene regions in a Mendelian 
randomization analysis, it is highly implausible that all the genetic variants satisfy the instrumental 
variable assumptions. This means that a simple instrumental variable analysis alone should not be 
relied on to give a causal conclusion. In this paper, we discuss a range of sensitivity analyses that 
will either support or question the validity of causal inference from a Mendelian randomization 
analysis with multiple genetic variants. We focus on sensitivity analyses of greatest practical 
relevance for ensuring robust causal inferences, and those that can be undertaken using 
summarized data. Aside from cases in which the justification of the instrumental variable 
assumptions is supported by strong biological understanding, a Mendelian randomization analysis 
in which no assessment of the robustness of the findings to violations of the instrumental variable 
assumptions has been made should be viewed as speculative and incomplete. In particular, 
Mendelian randomization investigations with large numbers of genetic variants without such 
sensitivity analyses should be treated with skepticism. 
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An instrumental variable in an observational study behaves similarly to random treatment 
assignment in an experimental setting.
1
 It provides a natural experiment, whereby individuals with 
different levels of the instrumental variable differ on average with respect to the putative risk 
factor, but not with respect to any confounders of the risk factor–outcome association.2 Mendelian 
randomization is the use of a genetic variant as a proxy for a modifiable risk factor.
3,4
 If a genetic 
variant satisfies the assumptions of an instrumental variable for the risk factor, then whether there 
is an association between the genetic variant and the outcome is a test of whether the risk factor is 
a cause of the outcome.
5
 
The instrumental variable assumptions are satisfied for a genetic variant if: 
 
i. the genetic variant is associated with the risk factor; 
 
ii. the genetic variant is not associated with confounders of the risk factor–outcome 
relationship; and 
iii. the genetic variant is not associated with the outcome conditional on the risk factor and 
confounders of the risk factor–outcome relationship.6 
These assumptions imply that the only causal pathway from the genetic variant to the outcome is 
via the risk factor, and there is no other causal pathway either directly to the outcome or via a 
confounder.
7
 A diagram corresponding to these assumptions is presented in Figure 1. 
We further assume that all valid instrumental variables identify the same causal parameter; we 
return to this assumption in the discussion. For this interpretation to hold, it is necessary for certain 
parametric assumptions to hold. In this paper, we assume that the effects of: i) the instrumental 
variables on the risk factor, ii) the instrumental variables on the outcome, iii) the risk factor on the 
outcome are linear without effect modification; and iv) the association of the genetic variant with 
the risk factor is homogeneous in the population.
5
 These assumptions are not necessary for the 
identification of a causal effect, but they ensure that the estimate from each instrumental variable 
targets the same average causal effect.
8
 Weaker assumptions can identify a local average causal 
effect;
9
 however, the local average causal effect is likely to differ for each instrumental variable. 
Although these assumptions are strict, the causal estimate from an instrumental variable analysis is 
a valid test statistic for the causal null hypothesis without requiring the assumptions of linearity, 
homogeneity, or monotonicity.
10
 In any case, the causal effect of intervention on a risk factor is 
likely to depend on several aspects of the intervention (for example, its magnitude, duration and 
pathway), and therefore will not precisely correspond to the estimate from a Mendelian 
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randomization analysis.
11
 Hence, we would urge practitioners to view the assessment of causality 
as the primary result of a Mendelian randomization, and not to interpret any causal estimate too 
literally.
12
 
We also assume that the genetic variants are mutually independent in their distributions, 
although extensions are available for most of the analysis methods in the case of correlated 
variants, provided that the correlation structure is known.
13
 
Genetic variants are particularly suitable candidate instrumental variables, as they are fixed at 
conception, and hence cannot be affected by environmental factors that could otherwise lead to 
confounding or reverse causation.
14
 However, there are many well-documented ways in which the 
instrumental variable assumptions may be violated for any particular genetic variant, such as 
pleiotropy, linkage disequilibrium, and population stratification.
3,15
 
For risk factors that are soluble protein biomarkers, there is often a gene region that encodes 
the protein (for example, the CRP gene region for C-reactive protein
16
), or a regulator or inhibitor 
of the protein (for example, the IL6R gene region for interleukin-6
17
). Using one or more variants 
from such a gene region as instrumental variables would be ideal for a Mendelian randomization 
analysis, as these genetic variants would be the most likely to satisfy the instrumental variable 
assumptions, and the most informative proxies for intervention on the risk factor.
18
 However, such 
genetic variants do not exist for many risk factors. 
The approach of using multiple genetic variants in different gene regions is particularly 
suitable for complex risk factors that are multifactorial and polygenic, such as body mass index,
19
 
height,
20
 or blood pressure.
21
 Summarized data (in particular, beta-coefficients and standard errors) 
on genetic associations with the risk factor can be combined with summarized data on genetic 
associations with the outcome (that are often publicly available for download) to provide causal 
effect estimates, under the assumption that the genetic variants are all instrumental variables.
22,23
 
Using multiple genetic variants increases the power of a Mendelian randomization investigation 
compared to an analysis based on a single variant.
24
 However, even if only one of the genetic 
variants is not a valid instrumental variable, the causal estimate based on all the variants from a 
conventional Mendelian randomization analysis will be biased and Type 1 (false positive) error 
rates will be inflated.
25,26
 
In this paper, we describe a range of sensitivity analyses that either support or question the 
validity of causal inference from a Mendelian randomization analysis with multiple genetic 
variants. These sensitivity analyses will be useful for judging whether a causal conclusion from 
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such an analysis is plausible or not. We focus on those sensitivity analyses that can be 
implemented using summarized data only. We consider approaches under two broad categories: 
methods for assessing the instrumental variable assumptions, and robust analysis methods that rely 
on a less stringent set of assumptions than a conventional Mendelian randomization analysis. 
We illustrate the approaches using the example of estimating the causal effect of C-reactive 
protein (CRP) on coronary artery disease (CAD) risk using 4 genetic variants in the CRP gene 
region,
16
 and using 17 genetic variants (eTable A1) that have been shown to be associated with 
CRP at a genome-wide level of significance in a large meta-analysis; 
see eFigure in ref.27
 beta-
coefficients represent per allele associations with log-transformed CRP concentrations. Genetic 
associations with CAD risk were taken from the CARDIoGRAM consortium;
28
 beta-coefficients 
represent per allele log odds ratios for CAD risk. Ethical approval for the analyses using 4 genetic 
variants in the CRP gene region was granted by the Cambridgeshire ethics review committee; for 
the analyses using 17 genetic variants associated with CRP concentrations and with CAD risk, 
ethical approval was granted to the constituent studies by local institutional review boards. 
For reference, the causal estimate based on the genetic variants in the CRP gene region is null 
(odds ratio 1.00, 95% confidence interval 0.90, 1.13 per 1 standard deviation increase in CRP 
concentrations [equal to a 1.05-unit increase in log-transformed CRP, or a 2.86-fold increase]), 
whereas the ‘causal’ estimate using an inverse-variance weighted method based on the genome-
wide significant variants (a less reliable approach)
22
 is negative (odds ratio 0.87, 95% confidence 
interval 0.79, 0.96 per 1 standard deviation increase). Software code for performing the proposed 
sensitivity analyses is provided in eAppendix A.1 and A.2; http://links.lww.com/EDE/B114. 
 
Assessing the instrumental variable assumptions 
 
The first set of approaches we consider are those to assess whether the instrumental variable 
assumptions are likely to be satisfied or not for a set of genetic variants. We consider in turn the 
assessment of the association with measured confounders, the exploitation of a natural experiment 
in the form of a gene–environment interaction, examination of a scatter plot combined with a 
heterogeneity test, and of a funnel plot combined with a test for directional pleiotropy. 
 
Use of measured covariates 
 
The assumption that an instrumental variable is not associated with confounders of the risk factor–
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outcome association is not fully testable, as not all confounders will be known or measured. 
However, the associations of genetic variants with measured covariates can be assessed. Lack of 
association of the instrumental variable with measured covariates does not imply lack of 
association with all confounders; however, an association with a measured covariate should be 
investigated carefully for a potential pleiotropic effect of the genetic variant. Figure 2, adapted 
from Wensley et al.,
16
 shows the associations of the 4 variants in the CRP gene region with a range 
of potential confounders. Associations are no stronger than would be expected by chance alone. 
If there are covariates that by biological considerations should be downstream consequences of 
the risk factor, then the associations of genetic variants with these covariates can be assessed as 
positive controls to give confidence that the function of the genetic variants matches the known 
consequences of the risk factor. For instance, inhibition of interleukin-1 by the drug anakinra has 
been observed to lead to decreased levels of C-reactive protein and interleukin-6 in clinical trials. 
If genetic variants associated with interleukin-1 are also associated with both these covariates, this 
makes it more plausible that the variants are good proxies of intervention on interleukin-1 levels.
29
 
A benefit of the use of multiple genetic variants is the possibility to differentiate between 
pleiotropy and mediation, two mechanisms by which a genetic variant may be associated with a 
measured covariate (Figure 3). If a genetic variant is associated with a covariate independently of 
the risk factor (pleiotropy, or ‘horizontal pleiotropy’), then the instrumental variable assumptions 
are likely to be violated and the genetic variant should be excluded from an instrumental variable 
analysis, as the association with the covariate is likely to open a causal pathway from the variant to 
the outcome not via the risk factor. However, if the genetic variant is associated with a covariate 
due to its association with the risk factor of interest (mediation, or ‘vertical pleiotropy’), and there 
is no alternative causal pathway from the variant to the outcome except for that via the risk factor, 
then the genetic variant is a valid instrumental variable.
23
 
For instance, if increasing body mass index leads to increased blood pressure, then genetic 
variants that are instrumental variables for body mass index should also be associated with blood 
pressure. If multiple genetic variants that are candidate instrumental variables for body mass index 
are all concordantly associated with blood pressure, then it is plausible that the associations are due 
to mediation, not pleiotropy. In contrast, if only one or two variants are associated with blood 
pressure, then this is likely to be a manifestation of pleiotropy. Pleiotropy and mediation are not 
mutually exclusive (both could occur for the same covariate), however, this approach may give an 
insight into whether the association relates to a single genetic variant or to variants associated with the 
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risk factor more widely. 
In some cases, valid causal inference may still be possible even if a genetic variant has a 
pleiotropic association with a measured covariate; for instance, by adjusting for the covariate in the 
analysis model. However, if the Mendelian randomization investigation is performed using 
summarized data, then the investigator is unlikely to be able to adjust for covariates. An alternative 
approach with summarized data is a multivariable Mendelian randomization analysis, in which 
genetic associations with the outcome are regressed on the genetic associations with the risk factor 
and covariates in a multivariable weighted regression model.
30
 
A practical difficulty of determining which variants to include in a Mendelian randomization 
analysis using measured covariates, aside from that of distinguishing between pleiotropy and 
mediation, is that of multiple testing. If there are large numbers of genetic variants and several 
measured covariates, then it is difficult to set a statistical significance threshold for rejecting a 
genetic variant as pleiotropic to balance between the desire to exclude invalid instrumental 
variables and the need to acknowledge the multiple tests. A sensible compromise is to consider 
multiple thresholds, for example a conservative threshold to maximize robustness (a fixed 
threshold such as P<0.01), and a liberal threshold to maximize power (such as a Bonferroni-
corrected threshold taking into account the number of comparisons made).
23
 A similar approach 
was previously taken to assess the causal role of lipid fractions on CAD risk.
31
 If no causal effect is 
detected even in a liberal analysis, then the plausibility of a null causal finding increases. 
 
Gene–environment interaction 
 
For some applications of Mendelian randomization, a further natural experiment may be available 
if the postulated causal effect is present in one stratum of the population, but absent in another.
32
 
For example, the association of alcohol-related genetic variants with esophageal cancer risk is 
present in those who drink alcohol, but absent in abstainers.
33
 A gene–environment interaction 
provides evidence that a genetic association with the outcome in the population is a result of the 
risk factor; if it were a result of pleiotropy, then it would be likely to be present in both strata of the 
population. Gene–environment interactions may be difficult to find, but can provide convincing 
evidence of a causal effect. 
One potential complication of such an analysis is the possibility of collider bias;
34
 by 
stratifying on the risk factor, associations between the genetic variants and the outcome may be 
distorted in the strata (in the examples above, in alcohol consumers/abstainers). To our knowledge, 
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no systematic investigation has been conducted as to the degree that collider bias may lead to 
inappropriate causal inferences in a Mendelian randomization setting, although sensitivity analyses 
to assess the potential bias in the context of instrumental variable analysis with a single instrument 
are available.
35, 36
 
 
Scatter plot and test for heterogeneity 
 
Even if the instrumental variable assumptions are in doubt for some or all of the variants, if several 
independent genetic variants in different gene regions are concordantly associated with the 
outcome, then a causal conclusion would seem reasonable.
37
 Although it is possible for the 
instrumental variable assumptions to be violated for all of the genetic variants, it is unlikely that 
pleiotropic effects for many different genetic variants would all result in the same direction of 
association with the outcome in the absence of an underlying causal effect of the risk factor.38 
This is particularly true if there is a dose–response relationship in the per allele associations with 
the risk factor and with the outcome. An example of this is the relationship between low-density 
lipoprotein cholesterol (LDL-c) and CAD risk.
see Figure 3 in ref.39
 Genetic variants having considerably 
different magnitudes and mechanisms of association with LDL-c concentrations, including rare 
loss-of-function variants with substantial effect sizes, have proportional associations with CAD 
risk. 
In a Mendelian randomization setting, a heterogeneity test is a statistical assessment of the 
compatibility of instrumental variable estimates based on individual genetic variants.
40
 In 
economics, this test is known as an overidentification test, as the same causal effect is identified by 
each of the instrumental variables.
41
 Heterogeneity can be assessed visually by a scatter plot of the 
genetic associations with the outcome ( ˆ
Y j
  for genetic variant 1,...,j J ) against the genetic 
associations with the risk factor ( ˆ
Xj
 ), together with their confidence intervals. Each point on these 
graphs represents a genetic variant, and the points should be compatible with a straight-line 
through the origin under the null. Any point that substantially deviates from this line should be 
investigated for potential pleiotropy. 
Scatter plots for the example of CRP and CAD risk are given in Figure 4; the plot using 
variants from the CRP gene region (left) demonstrates homogeneity of estimates, whereas the plot 
using genome-wide significant variants (right) demonstrates heterogeneity, with several clear 
outliers (although the genetic variants in the CRP gene region are partially correlated, so the 
homogeneity in the first case is somewhat artefactual). 
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A statistical test for heterogeneity can be performed using Cochran’s Q test on the causal 
estimates from each genetic variant 
ˆ
ˆ
ˆ
Y jIV
j
Xj



 , using the approximate standard errors 
ˆ( )
ˆ( )
ˆ
Y jIV
j
Xj
se
se



  . This can be performed in standard statistical software packages for inverse-
variance weighted meta-analysis. The statistic is calculated as: 
2ˆ ˆ( )IV IV
j j
j
Q w     
where 
ˆ
ˆ
IV
j jjIV
jj
w
w

 


 is the (fixed-effect) inverse-variance weighted estimate based on all the 
genetic variants, and 2ˆ( )IV
j j
w se    are the inverse-variance weights. This statistic can be calculated 
using only summarized data. It should have a chi-squared distribution with 1J   degrees of 
freedom under the null hypothesis of homogeneity. The amount of heterogeneity can also be 
expressed using the I
2
 statistic.
42
 Other heterogeneity tests include the Sargan test,
41
 which can be 
performed using individual-level data, or a likelihood ratio test using summarized data.
23
 An initial 
visual inspection for heterogeneity is important, as a formal statistical test may have low power 
particularly when there are few genetic variants.
43
 In the example of CRP and CAD risk, the Q 
statistic using genome-wide significant variants from across the genome is 71.9 (16 degrees of 
freedom, 95 10p   ), indicating substantial heterogeneity. 
The investigation of heterogeneity of causal estimates as an assessment of the instrumental 
variable assumptions relies on the assumption that all valid instrumental variables identify the 
same causal parameter. If not, then the heterogeneity test may over-reject the null. 
 
Funnel plot and test for directional pleiotropy 
 
A funnel plot (taken from the meta-analysis literature
44
) of the instrumental variable precisions 
ˆ
ˆ( )
Xj
Y j
se


 ( the reciprocal of the standard error of the instrumental variable estimate) against the 
instrumental variable estimates 
ˆ
ˆ
Y j
Xj


 should be a symmetric funnel, in which more precise 
estimates are less variable. Any asymmetry in the funnel plot is a sign of directional pleiotropy 
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(pleiotropic effects of genetic variants do not average to zero), meaning that causal estimates from 
the individual variants are biased on average. Although heterogeneity in causal estimates is 
concerning, provided that the pleiotropic effects of genetic variants are equally likely to be positive 
or negative, the overall causal estimate based on all the genetic variants may be unbiased. 
Directional pleiotropy is more serious, as it suggests that pleiotropic effects are not balanced, and 
thus that the overall causal estimate is biased. The funnel plot in the example of CRP on CAD risk 
for the genome-wide significant variants is shown in Figure 5. There is clear evidence of 
heterogeneity of causal effect estimates, but no evidence of departure from symmetry in this case. 
Egger regression is a method for detecting small study bias (often interpreted as publication 
bias) in a meta-analysis of separate studies.
45
 The method can also be used for detecting directional 
pleiotropy from separate genetic variants.
46
 This can be implemented by a weighted regression of 
the genetic associations with the outcome ( ˆ
Y j
 ) on the genetic associations with the risk factor ( ˆ
Xj

) weighted by the inverse-variance of the associations with the outcome ( 2ˆ( )
Y j
se   ).
47
 The genetic 
associations should be orientated so that the associations with the risk factor all have the same 
sign. If there is no intercept term in this regression, the slope parameter is the inverse-variance 
weighted causal estimate.
48
 If there is an intercept term (as in Egger regression), then under the 
InSIDE assumption (see later) the intercept is the average pleiotropic effect of a genetic variant; if 
the intercept differs from zero, then there is evidence of directional pleiotropy.
46
 In the example of 
CRP on CAD risk for the genome-wide significant variants, the p-value for the test of directional 
pleiotropy is 0.61, indicating no evidence of directional pleiotropy. 
 
Robust analysis methods 
 
The second category of sensitivity analyses is that of robust analysis methods. Robust analysis 
methods allow different (and when the main purpose is to test the causal null hypothesis, weaker) 
assumptions than standard instrumental variable methods. In turn, we consider penalization 
methods, median-based methods, and Egger regression. 
 
Penalization methods 
 
We first consider methods in which the contribution of some genetic variants (for example, 
heterogeneous or outlying variants) to the analysis is downweighted (or penalized). If the causal 
conclusion from a Mendelian randomization investigation depends only on a single genetic variant 
(particularly if the estimate from this variant is heterogeneous with those from other variants) then 
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the result may be driven by a pleiotropic effect of that particular variant and not by the causal 
effect of the risk factor. 
The simplest way of performing a penalization method is to omit some of the variants from the 
analysis. This could be done systematically. For example, with a small number of genetic variants, 
the causal estimates omitting one variant at a time could be considered. Alternatively, it could be 
done stochastically. For example, we could consider estimates omitting (say) 30% of the genetic 
variants at a time by selecting the 30% of variants at random a large number of times, and 
calculating the causal estimate in each case. This sensitivity analysis has been undertaken for the 
effect of LDL-c on aortic stenosis.
see eFigure in ref.49
 If the spread of results includes only (say) positive 
effect estimates, then we can be confident that the overall finding does not depend only on the 
influence of a few variants. However, even if only a small proportion of the estimates are 
discordant, these cases should be investigated and the omitted variants leading to the discordant 
estimates should be carefully investigated for potential violations of the instrumental variable 
assumptions. The causal estimates for the example of CRP on CAD risk based on the genome-
wide significant variants using the inverse-variance weighted method are displayed in Figure 6. 
Two of the 17 variants are omitted from the analysis in turn in a systematic way, and then the 136 
resulting estimates are arranged in order of magnitude. The overall estimate excluding the two 
strongest variants with negative causal estimates is positive, indicating that the overall negative 
finding based on all the variants seems to be driven by these two variants, and is not supported by 
the majority of variants. 
A more focused approach to omitting genetic variants is to omit genetic variants from the 
analysis with heterogeneous instrumental variable estimates. This could be done by calculating the 
contribution to Cochran’s Q statistic for each genetic variant, and omitting any variant whose 
contribution to the statistic is greater than the upper 95th percentile of a chi-squared distribution on 
one degree of freedom (3.84). This approach has been applied for investigating the causal effect of 
lipid fractions on CAD risk.
50
 More formal penalization methods have been proposed using L1-
penalization to downweight the contribution of outlying variants to the analysis in a continuous 
way.
51,52
 These methods have desirable theoretical properties, giving consistent estimates of the 
causal effect even if up to half of the genetic variants are not valid instrumental variables. 
However, they require individual-level data and a one-sample setting (genetic variants, risk factor 
and outcome measurements are available for the same individuals). 
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Median-based methods 
 
An alternative family of methods that gives consistent estimates when up to half the genetic 
variants are not valid instrumental variables, but that can be performed using summarized data 
rather than individual-level data, are median-based methods. If 50% or more of the genetic variants 
are valid instrumental variables, then the instrumental variable estimates for these variants will all 
be consistent estimates of the causal effect. In particular, this implies that the median of all the 
instrumental variable estimates based on the individual genetic variants will be a consistent 
estimate.
51
 
However, the median estimate is likely to be inefficient, as the individual instrumental variable 
estimates from each genetic variant receive equal weight in the analysis. An alternative is to 
construct a weighted median estimate, defined as the median of an empirical distribution in which 
each instrumental variable estimate appears with probability proportional to the inverse of its 
variance.53 Then, more precise instrumental variable estimates receive more weight in the 
weighted median function. The weighted median estimate is consistent under the assumption that 
genetic variants representing over 50% of the weight in the analysis are valid instruments. This is a 
subtly different assumption to the assumption that over 50% of the genetic variants are valid 
instruments, although it is not clear that one or other of the assumptions is more plausible 
generally. Confidence intervals for the median and weighted estimates can be estimated using 
bootstrapping. 
Egger regression 
 
The Egger regression method was introduced above as a test for directional pleiotropy; this test 
does not make any assumption about the genetic variants. However, under an assumption that is 
weaker than standard instrumental variable assumptions, the slope coefficient from the Egger 
regression method provides an estimate of the causal effect that is consistent asymptotically 
even if all the genetic variants have pleiotropic effects on the outcome.
46
 This is the assumption 
that pleiotropic effects of genetic variants (that is, direct effects of the genetic variants on the 
outcome that do not operate via the risk factor) are independent of instrument strength (known 
as the InSIDE assumption – Instrument Strength Independent of Direct Effect). This same 
assumption was considered by Kolesár et al. with individual-level data.
54
 The motivation for the 
Egger regression method is that, under the InSIDE assumption, stronger genetic variants should 
have more reliable estimates of the causal effect than weaker variants. Once the average 
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pleiotropic effect of variants is accounted for through the intercept term in Egger regression, 
any residual dose–response relationship in the genetic associations provides evidence of a 
causal effect. The Egger regression estimate is consistent under the InSIDE assumption as the 
sample size tends to infinity if the correlation between the direct effects and instrument strength 
is exactly zero; otherwise it is consistent as the sample size and the number of genetic variants 
both tend to infinity. As previously stated, Egger regression assumes linearity and homogeneity 
in the associations between the genetic variants, risk factor and outcome. 
The InSIDE assumption may not be satisfied in practice, particularly if the pleiotropic effects 
of genetic variants on the outcome act via a single confounding variable. There is some evidence 
for the general plausibility of the InSIDE assumption, as associations of genetic variants with 
different phenotypic variables have been shown to be largely uncorrelated in an empirical study.
55
 
The Egger regression estimate may have much wider confidence intervals than those from other 
methods in practice, as it relies on variants having different strengths of association with the risk 
factor. A situation with many independent genetic variants having identical magnitudes of 
association with the risk factor and with the outcome would intuitively provide strong evidence of 
a causal effect; however, the Egger estimate in this case would not be identified. 
The Egger regression method gives consistent estimates if all the genetic variants are invalid 
instruments provided that the InSIDE assumption is satisfied, whereas the penalization and 
median-based methods rely on over half of the genetic variants being valid instrumental variables 
for consistent estimation. However, the penalization and median-based methods allow more 
general departures from the instrumental variable assumptions for the invalid instruments. In 
practice, it would seem prudent to compare estimates from a range of methods. If all methods 
provide similar estimates, then a causal effect is more plausible. For example, using genetic 
variants chosen solely on the basis of their association with the risk factor, a broad range of 
methods affirmed that LDL-c was a causal risk factor for CAD risk. However, the causal effect of 
HDL-c on CAD risk suggested by a liberal Mendelian randomization analysis using the inverse-
variance weighted method (see also 
31
) was not supported by robust analysis methods.
53
 The 
median-based and Egger regression methods have also been shown to have lower Type 1 (false 
positive) error rates than the inverse-variance weighted method in simulation studies with some 
invalid instrumental variables for finite sample sizes,
46,53
 although they were above the nominal 
level in the case of directional pleiotropy (for the median method), and when the InSIDE 
assumption was violated (for the Egger regression method). 
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Example: C-reactive protein and coronary artery disease risk 
 
The robust methods described in this paper were applied to the example of CRP and CAD risk 
using genome-wide significant variants; the code for performing these analyses is given in 
eAppendix A.3; http://links.lww.com/EDE/B114. The inverse-variance weighted method was 
originally proposed as a fixed-effect meta-analysis of the causal estimates from each of the genetic 
variants.
21,22,48
 However, if there is heterogeneity between the causal estimates of different variants 
(as is the case here), a random-effects model would be more appropriate. In Egger regression, 
heterogeneity is expected as genetic variants that are not valid instrumental variables but satisfy 
the InSIDE assumption will give heterogeneous causal estimates. We consider fixed-effect and 
multiplicative random-effects models for both the inverse-variance weighted and Egger regression 
methods.
56
 Also, we consider simple (that is, unweighted) median and weighted median estimates. 
The fixed-effect inverse-variance weighted and Egger regression estimates suggest an inverse 
causal effect of CRP on CAD risk (Table 1). However, the corresponding random-effects analyses 
imply that there is no convincing evidence for a causal effect. Moreover, the simple median 
estimate is in the opposite direction. This arises because, although the strongest genetic variants 
have negative causal estimates, the majority of genetic variants have positive causal estimates. The 
inconsistency of the estimates from different methods indicates that the genome-wide significant 
variants for CRP are not all valid instrumental variables, and that a causal conclusion based on 
these variants would be unreliable. 
 
Discussion 
 
When multiple genetic variants from different gene regions are used in a Mendelian randomization 
analysis, it is highly implausible that all the genetic variants satisfy the instrumental variable 
assumptions. This does not preclude a causal conclusion; however, it means that a simple 
instrumental variable analysis alone should not be relied on to give a causal conclusion. 
Inappropriate and naive application of standard Mendelian randomization methods may lead to 
exactly the same problems of unmeasured confounding that the technique was designed to avoid. 
In this paper, we have discussed a range of sensitivity analyses that can be used to question the 
plausibility of a Mendelian randomization analysis using multiple variants, focusing on those 
analyses which are judged to be most useful to an applied analyst and those that can be performed 
using summarized data. The different approaches are summarized in Table 2. Not every sensitivity 
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analysis may be appropriate for each case, but some effort should be made to investigate whether a 
causal finding is robust to violations of the instrumental variable assumptions. 
 
Comparison with previous literature 
 
From its initial popularization, proponents of Mendelian randomization have been candid about the 
stringent and untestable assumptions required in Mendelian randomization.
3,14
 However, applied 
investigations have not always reflected this need for caution. In comparison with previous 
attempts to offer robust approaches for causal inference in Mendelian randomization, we have here 
repeated some of the guidance of Glymour et al.,
32
 specifically relating to the search for gene–
environment interactions and to testing for heterogeneity between the estimates from different 
variants. We have not discussed the use of bounds for instrumental variable estimates
57
 (as these 
are usually uninformative in all but the most pathological cases, and cannot be calculated when the 
risk factor is continuous
5
), and the adjustment of gene–outcome associations for the risk factor. 
Substantial attenuation of the association on adjustment for the risk factor is expected if the genetic 
variant is a valid instrumental variable; however, such attenuation may not occur in practice, for 
example due to measurement error in the exposure
58
 – conversely, some attenuation may occur for 
an invalid instrumental variable. VanderWeele et al.
10
 suggest using Mendelian randomization as a 
test for a causal effect without providing an effect estimate, and provide a sensitivity analysis for a 
pleiotropic effect on an unmeasured confounder. However, this sensitivity analysis is only 
designed for use with a single genetic variant, so it cannot be applied in the majority of cases. 
Much of the criticism of VanderWeele et al. over the precise definition of the causal parameter 
estimated in Mendelian randomization is warranted, although a response would be to have a less 
literal interpretation of effect estimates in Mendelian randomization and to view the primary 
finding from a Mendelian randomization investigation as the assessment of causation rather than 
the estimation of a causal effect. Violations of the assumptions of homogeneity and/or linearity of 
the causal effect would also lead to difficulties in interpreting the causal estimate, although they 
are unlikely to lead to inappropriate causal inferences or inflated Type 1 error rates under the 
null.
59
 A causal estimate is useful to combine and compare evidence from multiple genetic 
variants, but it can be primarily interpreted as a test of the null hypothesis of no causal effect and 
only secondarily as a guide to the expected result of intervening on the risk factor in practice. As 
such, we regard violations of the instrumental variable assumptions necessary for valid causal 
inferences as first-order concerns, but violations of the assumptions necessary for the estimation of 
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a causal effect as second-order concerns. 
 
Summarized data and two-sample Mendelian randomization 
 
Although the opportunities to assess the validity of genetic variants as instrumental variables are 
inherently less than if individual-level data were available, all of the sensitivity analyses discussed 
in this paper can equally be performed using summarized data (although assessing associations 
with covariates may be difficult to do in a consistent way or in a consistent set of individuals, and 
summarized data for assessing a gene–environment interaction is unlikely to be routinely made 
available). A further concern with summarized data is the use of two-sample analyses, in which 
data on the gene–risk factor and gene–outcome associations are taken from non-overlapping 
datasets.
60
 It is important in this case that the two samples are similar, particularly with regard to 
ethnic origin, as it is necessary for the instrumental variable assumptions to hold in both samples, 
as well as for estimates from each sample to be relevant to the other sample. This is not to 
discourage the use of summarized data or two-sample Mendelian randomization analyses, but to 
acknowledge that the bar for evidential quality is even higher in this case. 
 
Genetic variants with different functional effects 
 
In this paper, we have assumed that there is a single causal effect of the risk factor on the outcome, 
and interpreted deviation from this (that is, heterogeneity of causal effect estimates) as evidence 
that the instrumental variable assumptions are violated for some of the genetic variants. In reality, 
if genetic variants have different functional effects on the risk factor, then different magnitudes of 
causal effect may be expected. For instance, genetic variants associated with body mass index may 
have different biological mechanisms giving rise to the association, and may affect the outcome to 
different extents. Heterogeneity between causal estimates based on sets of genetic variants grouped 
according to their biological function may help reveal which mechanisms are causal.
61
 
Alternatively, different causal effects may arise under failure of the assumptions of homogeneity 
of the genetic association with the risk factor or linearity of the effect of the risk factor on the 
outcome. In this case, the causal estimates presented in this paper still provide a valid test of the 
causal null hypothesis, but do not have an interpretation as estimates of a causal parameter.
12
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Pleiotropy and other violations of the instrumental variable assumptions 
In this paper, we have discussed violations of the instrumental variable assumptions primarily 
using the language of pleiotropy. Some other ways in which the instrumental variable assumptions 
may be violated (such as linkage disequilibrium with another functional variant) can also be 
expressed in terms of pleiotropy, and so these situations can be dealt with similarly. In particular, 
violations of the exclusion restriction assumption (that is, no effect of the genetic variant on the 
outcome except for that via the risk factor) can be expressed as pleiotropic effects.
62
 A notable 
exception is population stratification, which can be best addressed by choice of study population (a 
population of uniform ethnicity should be used whenever possible). Population stratification is 
commonly addressed by the adjustment in the genetic association analyses for genome-wide 
principal components.
63
 While this adjustment has proved successful in some cases, it is not 
guaranteed to eliminate population stratification. Another potential source of bias that does not 
correspond to pleiotropy is selection bias, including sample ascertainment and informative 
censoring.
64
 
Further potential problems for Mendelian randomization that have been identified include 
measurement error in the risk factor, and multiple versions of the risk factor.
32
 Classical (non-
differential, zero-mean) measurement error in the risk factor does not lead to bias in instrumental 
variable estimates.
65
 As the misspecification of weights in an allele score does not lead to 
inappropriate causal inferences,
25
 it is likely that any plausibly realistic pattern of measurement 
error would not lead to inflation of Type 1 error rates under the null. If there are multiple versions 
of the risk factor, then this would lead to difficulties in interpreting the causal findings. For 
example, if body mass index is treated as the risk factor in the analysis, but in fact the true causal 
risk factor is abdominal obesity (or some other more specific measure of obesity), then the 
sensitivity analyses of this paper would be appropriate for assessing the validity of a causal 
finding, assuming that the surrogate risk factor (here, body mass index) and the true causal risk 
factor (here, abdominal obesity) are correlated. However, they will not help to identified the 
specific causal risk factor; only biological knowledge can help here. 
We expect the sensitivity analyses discussed in the paper to be able to detect violations of the 
instrumental variable assumptions regardless of how these violations arise, although it is unlikely 
that the some consistency properties of the robust analysis methods (in particular the Egger 
regression method) will hold. 
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Conclusion 
 
In conclusion, the increasing size and coverage of genome-wide association studies and the 
increasing availability of summarized data on genetic associations are making the application of 
Mendelian randomization simpler. However, consideration must be given as to the robustness of 
findings to violations of the instrumental variable assumptions. Although no method can provide 
an infallible test of causation, the methods for sensitivity analysis described in this paper will help 
to judge whether a causal conclusion from a Mendelian randomization analysis is reasonable or 
not. Aside from cases in which the selection of the genetic variants and their justification as 
instrumental variables is motivated by strong biological understanding, a Mendelian randomization 
analysis in which no assessment of the robustness of the findings has been made should be viewed 
as speculative. 
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Key messages: 
 
• Mendelian randomization investigations are becoming more powerful and simpler 
to perform, due to the increasing size and coverage of genome-wide association 
studies and the increasing availability of summarized data on genetic associations 
with risk factors and disease outcomes. 
• However, when using multiple genetic variants from different gene regions in a 
Mendelian randomization analysis, it is highly implausible that all the genetic 
variants satisfy the instrumental variable assumptions. 
 
• This means that a simple instrumental variable analysis alone should not be relied 
on to give a causal conclusion. 
• In this paper, we discuss a range of sensitivity analyses that will either support or 
question the validity of causal inference from a Mendelian randomization analysis 
with multiple genetic variants. 
• Aside from cases in which the justification of the instrumental variable 
assumptions is supported by strong biological understanding, a Mendelian 
randomization analysis in which no assessment of the robustness of the findings to 
violations of the instrumental variable assumptions has been made should be 
viewed as speculative and incomplete. 
• In particular, Mendelian randomization investigations with large numbers of 
genetic variants without such sensitivity analyses should be treated with 
skepticism. AC
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Figure legends 
 
Figure 1: Diagram of instrumental variable assumptions for Mendelian randomization. The 
three assumptions (i, ii, iii) are illustrated by the presence of an arrow, indicating the effect of one 
variable on the other (assumption i), or by a dashed line with a cross, indicating that there is no 
direct effect of one variable on the other (assumptions ii and iii). 
Figure 2: Associations (estimates in standard deviation units and 95% confidence intervals) of 
4 genetic variants in the CRP gene region with a range of covariates per C-reactive protein 
increasing allele. Adapted from Wensley et al.
16
 
Figure 3: Diagram to illustrate the difference between pleiotropy (left, the association of the 
genetic variant with the covariate is independent of the risk factor) and mediation (right, the 
association of the genetic variant with the covariate is mediated entirely via the risk factor). 
Figure 4: Scatter plots of genetic associations with the outcome against genetic associations 
with the risk factor (lines represent 95% confidence intervals) for Mendelian randomization 
analysis of C-reactive protein on coronary artery disease risk using: (left) genetic variants in the 
CRP gene region; (right) genetic variants throughout the genome that have been demonstrated as 
associated with C-reactive protein at a genome-wide level of significance. 
Figure 5: Funnel plot of instrument precision 
ˆ
ˆ( )
Xj
Y j
se


 against instrumental variable estimates 
for each genetic variant separately 
ˆ
ˆ
Y j
Xj


 for Mendelian randomization analysis of C-reactive protein 
on coronary artery disease risk using genetic variants throughout the genome that have been 
demonstrated as associated with C-reactive protein at a genome-wide level of significance. 
Horizontal lines represent 95% confidence intervals for the instrumental variable estimates. Solid 
vertical line is at the null; dashed vertical line is the (fixed-effect) inverse-variance weighted 
estimate. 
Figure 6: Estimates (ordered by magnitude) of causal effect of CRP on CAD risk from inverse-
variance weighted method using 17 genome-wide significant genetic variants omitting variants 
systematically 2 at a time. 
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Table 1: Estimates of causal effect of C-reactive protein on coronary artery disease risk based on 17 
genome-wide significant variants. 
 
Analysis method 
Log odds ratio per unit 
increase a 
(standard error) 
Odds ratio per 1-SD increase 
b 
(95% confidence interval) 
Inverse-variance weighted, fixed-effect −0.135 (0.048) 0.87 (0.79, 0.96) 
Inverse-variance weighted, random-
effects 
−0.135 (0.102) 0.87 (0.70, 1.07) 
Egger regression, fixed-effect −0.223 (0.091) 0.79 (0.66, 0.95) 
Egger regression, random-effects −0.223 (0.198) 0.79 (0.53, 1.19) 
Simple median 0.118 (0.155) 1.13 (0.83, 1.55) 
Weighted median −0.303 (0.109) 0.73 (0.58, 0.92) 
 
 aLog odds ratio for coronary artery disease per unit increase in log-transformed C-reactive protein 
concentration (equivalent to a 2.72-fold increase in C-reactive protein concentration). 
 bOdds ratio for coronary artery disease per 1-standard deviation (SD, 1.05-unit) increase in log-
transformed C-reactive protein concentration (equivalent to a 2.86-fold increase in C-reactive 
protein concentration). 
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Table 2: Summary of sensitivity analyses considered in this paper, and limitations of each of the 
proposed analyses. 
 
Sensitivity analysis Description 
Use of measured 
covariates 
Assess the associations of genetic variants with a range of measured 
confounders. Adjustment for measured covariates (in individual-level 
data, or via multivariable Mendelian randomization) may be a 
worthwhile sensitivity analysis in some cases, although careful choice 
of covariate adjustment is required. Limitations are that only measured 
confounders can be assessed, pleiotropy and mediation cannot be 
empirically distinguished, and multiple testing when there are large 
numbers of variants and confounders. 
Gene–
environment 
interaction 
Assess the association of genetic variants with the outcome in strata of 
the population in which the causal effect should be present and absent. 
Limitation is that such strata may not exist in many cases. 
Scatter plot and 
test for 
heterogeneity 
Assess the similarity of causal estimates from different genetic variants 
using visual and statistical tests. Limitation is power to detect 
heterogeneity, and that heterogeneity will be overestimated if the 
genetic variants are all valid instruments, but identify different 
magnitudes of causal effect (for instance, if the linearity and/or 
homogeneity assumptions are violated). 
Funnel plot and 
test for directional 
pleiotropy 
Assess whether causal estimates from different genetic variants are 
correlated with instrument strength using visual and statistical tests. 
Limitation is power to detect directional pleiotropy, and that 
asymmetry of a funnel plot does not necessarily imply violation of the 
instrumental variable assumptions. 
Penalization 
methods 
Estimate the causal effect downweighting the contribution of some 
variants, either i) systematically, ii) stochastically, or iii) if they have 
heterogeneous effect estimates. A formal method based on the third 
approach can give consistent estimates of the causal effect if up to 50% 
of the genetic variants are not valid instrumental variables. Limitations 
include the assumption that the majority of genetic variants are valid 
instrumental variables. 
Median-based 
methods 
Estimate the causal effect from each genetic variant, then calculate the 
median estimate, or a weighted median estimate. This estimate is 
consistent if at least 50% of the genetic variants (or variants 
comprising 50% of the weight for a weighted analysis) are valid 
instrumental variables. Limitations include inflated Type 1 error rates 
(although much improved compared with the inverse-variance 
weighted method), particularly when pleiotropic effects of genetic 
variants are not symmetrically distributed around zero. 
Egger regression 
method 
Estimate the causal effect using weighted linear regression with an 
intercept term to account for directional pleiotropy. This estimate is 
consistent under the InSIDE assumption (instrument strength is 
independent of direct effect). Limitations include assumptions of 
linearity and homogeneity, inflated Type 1 error rates if the InSIDE 
assumption is violated, and limited power to detect a causal effect, 
particularly if the genetic variants have similar magnitudes of 
association with the risk factor. 
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Figure 1. 
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Figure 2. 
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Figure 3. 
 
 
  
AC
CE
PT
ED
  
Figure 4a. 
 
 
Figure 4b. 
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Figure 6. 
 
AC
CE
PT
ED
